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Background and PurposezzThis work was undertaken to review the current cost-effectiveness 
analysis data on thrombolysis by intravenous (IV) therapy with recombinant tissue plasminogen 
activator (rtPA) for acute ischemic stroke.
MethodszzPubMed was searched for articles published between 1995 and 2008. The cost-effec-
tiveness analysis data from eight eligible studies were reviewed, paying particular attention to their 
modeling assumptions and the quality of the source data.
ResultszzThe reviewed studies were from six countries: USA (n=2), UK (n=2), Canada (n=1), 
Australia (n=1), Spain (n=1), and Denmark (n=1); most were performed from the healthcare-
system and/or societal perspectives. IV rtPA was associated with an acceptable increase in short-
term cost [range: US$ 36-236/patient; US$ 29,148-55,591/quality-adjusted life-years (QALYs)], 
and a net long-term cost saving that was higher from a societal perspective (range: -US$ 12,043 
to -US$ 630/patient; -US$ 207,253 to -US$ 21,938/QALYs) than from a healthcare-system per-
spective (range: -US$ 5,811 to -US$ 5,415/patient; -US$ 41,137 to -US$ 4,662/QALYs).
ConclusionszzIV rtPA seems to be a cost-effective strategy for the management of acute isch-
emic stroke, and might reduce the associated healthcare costs as well as patients’ disabilities. Fur-
ther cost-effectiveness research and the development of a public health strategy are warranted to 
optimize the use of rtPA in Korea.  J Clin Neurol 2010;6:117-126
Key Wordszz  thrombolysis, stroke, recombinant tissue plasminogen activator, 
cost-effectiveness analysis.
Introduction
Stroke is the second leading cause of death in Korea, after can-
cer, accounting for around 15% of all deaths. A study with a 
nationally representative inpatient sample found that isch-
emic stroke was the most common subtype, accounting for 
62.9% of all strokes, and that more than 62.8% of Korean 
patients with first-ever ischemic stroke survived to 6 years.
1 
However, patients who survive a stroke are often left with per-
manent disabilities and an impaired quality of life,
2 and have 
significant needs for rehabilitation and long-term care that in-
evitability lead to increased healthcare costs.
There has been no systematic study of the cost or burden 
of illness incurred by strokes in Korea. However, it is highly 
likely that ischemic stroke places a considerable economic 
burden on society in terms of direct medical cost. Studies from 
Western countries estimate that stroke alone accounts for 2- 
5% of the total healthcare expenditure.
3,4 Although the data 
are not directly comparable, considering the higher incidence 
of stroke relative to cardiovascular disease in Korea, the pro-
portion of burden attributed to stroke care in Korea might be 
more than that in Western countries. This highlights a need for 
further economic evaluations to ensure that resources are allo-
cated efficiently to the treatment of ischemic stroke in Korea.
Faced with soaring healthcare costs, which threaten the fi-
nancial stability of National Health Insurance, there is an in-Cost-Effectiveness of Plasminogen Activator
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creasing demand in Korea for financial evaluations of health-
care interventions to enable the formulation and implemen-
tation of guidelines for clinical practice, and ischemic stroke 
is no exception. However, thus far there have been few cost-ef-
fectiveness studies conducted in Korea, primarily due to a lack 
of sufficient clinical and cost data. In contrast, numerous cost-
effectiveness studies on ischemic stroke have been conducted 
in other countries, including primary prevention,
5-8 diagnostic 
testing (echocardiography and carotid ultrasound,
9,10 and sc-
reening for deep vein thrombosis by ultrasound
11), mechanical 
thrombectomy,
12 thrombolysis,
13-20 secondary prevention,
21-24 
rehabilitation,
25,26 and management systems.
27,28
In this systematic review, we summarize the current data on 
the cost-effectiveness of intravenous (IV) thrombolysis by re-
combinant tissue plasminogen activator (rtPA; e.g., alteplase) 
for acute ischemic stroke. We have chosen this topic because 
it is not only a treatment with well-established efficacy,
29,30 but 
improving the IV rtPA treatment rate and performance requ-
ires greater healthcare resource allocation. Two previous sys-
tematic reviews, published in 1999
31 and 2004,
32 covered the 
cost-effectiveness of IV rtPA. However, given the consider-
able time that has elapsed since these studies were published, 
we believe that there is a considerable need to revisit the cost-
effectiveness of rtPA, taking into account more results from 
various data sources and modeling approaches. The aim of 
this study was to summarize the results of the economic im-
pact of IV rtPA, and to interpret the results in the context of the 
qualities and methods of the various studies.
Methods
An electronic, PubMed-based search of articles published be-
tween 1995 and 2008 was conducted using a combination of 
the following keywords: stroke, thrombolysis, plasminogen ac-
tivator, cost-effectiveness, and cost. Additional studies were 
sought among the citations of the papers retrieved as a result 
of that initial search. The search included published, model-
based, full-economic-evaluation studies regarding the use of 
IV thrombolysis by rtPA in a first-ever acute ischemic stroke 
setting. Exclusion criteria were non-English articles and re-
view articles. After screening the abstracts and whole articles, 
eight were found to comply with the study criteria. The qual-
ities of the selected studies were evaluated using a checklist 
based on other studies. Disagreements between the reviewers 
were resolved in a consensus meeting.
To enable comparison and summary of the study results, the 
incremental cost-effectiveness ratio (ICER) values and net cost 
of each study were recalculated to reflect the current values 
in US dollars (US$). If the study results were reported in a 
currency other than US$, the mean exchange rate during the 
year of publication was applied to convert them to US$.
33 The 
data were then multiplied by the inflation rate in the USA be-
tween the year of publication and the year 2009 to reflect the 
current value.
34 The results are presented according to the 
time horizon considered (1-year vs. 30-years or lifetime) and 
the perspective from which the study was taken (i.e., health 
system vs. societal).
Results
Study design and perspective
All of the studies included in this review employed a cost util-
ity analysis (CUA). Utility analysis is viewed as a particular-
ly useful technique because it allows for given treatment out-
comes to be adjusted for the health-related quality of life, while 
simultaneously providing a generic outcome measure for com-
parison of costs and outcomes in different programs. The ge-
neric outcome, which is usually expressed in quality-adjusted 
life-years (QALYs), is determined by adjusting the length of 
time affected by the health outcome according to the utility 
value of the resulting level of health status. Other generic out-
come measures, such as disability-adjusted life-years (DALYs) 
and healthy years equivalent, have been proposed as alterna-
tives to the QALY.
Considering the importance of the perspective of an evalu-
ation study, it was remarkable that seven of the eight studies 
explicitly mentioned the perspective used. Two studies were 
performed from the societal perspective (i.e., all costs and ef-
fects were included regardless of who incurred the costs and 
who obtained the effects),
16,18 and four studies (and one other 
study that did not explicitly mention the perspective
17) were 
performed from the healthcare-system perspective.
12,13,15,19 The 
studies assessed only the direct medical costs of rtPA treatment 
for stroke. One study was performed from both the health-
care-system and societal perspectives.
14
General characteristics
The studies provided data regarding the cost-effectiveness of 
thrombolysis treatment for stroke for six countries: USA (n= 
2), UK (n=2), Canada (n=1), Australia (n=1), Spain (n=1), and 
Denmark (n=1). The national healthcare systems in different 
countries appear diverse, and so the components of cost evalu-
ated by these studies differ markedly.
 
Modeling techniques
This systematic review concentrates on model-based econom-
ic evaluation studies. A model-based approach is necessary 
to estimate the long-term cost impact and consequences of 
interventions as well as the impact on the economic results 
of varying assumptions about risks of events, effectiveness of  Jung KT et al.
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therapy, the cost of the intervention itself, and patient care.
Five studies used a Markov modeling approach to evaluate 
the cost-effectiveness of rtPA treatment for stroke. Another th-
ree studies used a discrete-event simulation model, the Model 
of Resource Utilization, Costs, and Outcomes for Stroke (MO-
RUCOS), and the Stroke Outcome Model (SOM), but both 
of these simulation models use a semi-Markov modeling ap-
proach. Markov models are based on a series of “states” that 
a patient can occupy at a given point in time. Time elapses 
explicitly in a Markov model, with the probability of a patient 
occupying a given state assessed over a series of discrete time 
periods, called cycles. The length of these cycles vary with the 
disease and intervention being evaluated, but can be a certain 
number of months or even years. Each state in the model has 
a cost associated with it and, for CUA, a utility value. The du-
ration of time during which the average patient occupies the 
various states in the model will-when weighted according to 
the relevant cost or utility-be used to calculate expected costs 
and outcomes. The rate with which patients move between the 
states in the model is determined by a set of transition proba-
bilities.
Fagan et al.
13 and Sinclair et al.
14 developed a model to de-
scribe the short- and long-term outcomes of hospitalization. 
During hospitalization, the risk of symptomatic intracranial 
hemorrhage or death varied according to whether rtPA thera-
py was chosen. The 30-year time horizon was chosen in both 
of those studies. Sandercock et al.
16 used a Markov modeling 
approach to predict the health and economic outcome of rtPA 
and standard care groups. The Markov model used age-specif-
ic mortality, risk of recurrent stroke, and stroke-specific case-
fatality to estimate the probabilities of being dead, dependent, 
and independent at the beginning of each year. The Markov 
process was run repeatedly in 1-year cycles until the end of the 
cohort lifetime, and totals were computed for the accumulat-
ed health outcomes and costs. Mar et al.
19 employed a cycle 
length of 1-year and the whole life as the time horizon. The 
probabilities of transition to other states changed depending 
on the type of stroke. The states of stroke were transitory, 
since at the end of the 1-year cycle all patients had moved to 
another state (i.e., death, autonomy, or disability). Ehlers et 
al.
20 designed a decision tree with Markov modeling of the 
long-term consequences, which calculated the marginal cost-
effectiveness ratio for time spans of 1, 2, 3, and 30-years. The 
model assumes that the patient can receive either thromboly-
sis or conservative treatment. Depending on the treatment in-
stituted, the patient is exposed to a different risk of intracrani-
al hemorrhage.
Other studies adopted modeling approaches other than the 
simple Markov modeling approach. Chambers et al.
15 de-
signed the SOM. The SOM comprises two modules: acute 
care and long-term care/prevention of recurrence among st-
roke survivors. A prototype primary prevention module has 
also been developed. The model was constructed so that results 
from the long-term care/prevention of recurrence module 
could be used as a payoff in the acute care module. This design 
allowed both the long-term consequences of acute events and 
interventions during acute care to be considered. Stahl et al.
17 
conducted a discrete-event simulation model of the process of 
stroke care from symptom onset through administration of rtPA. 
A literature review was performed to determine the process 
ties, performance of CT, health outcomes, and cost estimates. 
The model assumed that the patient received either a Nation-
al Institute of Neurological Disorders and Stroke (NINDS)-
compliant strategy (i.e., evaluation by an emergency physi-
cian within 10-minutes, interpretation of CT scans within 
45-minutes, and administration of rtPA within 1-hour of presen-
tation) or current practice. Moodie et al.
18 designed the MO-
RUCOS system, which is a detailed model consisting of four 
modules (natural history, costs, outcomes, and interventions) 
that was developed through a series of linked spreadsheets. In 
this model, interventions were assumed to be operating in a st-
eady state (i.e., fully implemented and operating in accordance 
with efficacy potential), and they were applied to all eligible 
patients who presented during a 1-year period. Interventions 
were applied for a duration that realistically reflected their re-
al-world use. The time horizon for tracking-associated costs 
and consequences extended over the lifetime of the target pop-
ulation (Table 1).
Data sources
Fagan et al.,
13 Sinclair et al.,
14 Stahl et al.,
17 Mar et al.
19 estimat-
ed the outcomes (with or without rtPA treatment) based on the 
NINDS trial, which was a randomized, double blind, placebo-
controlled trial evaluating the short- and long-term outcomes 
of tissue plasminogen activator (tPA) in 624 patients with 
acute ischemic stroke. Moodie et al.
18 used stroke incidence, 
mortality, and service utilization data from the North East 
Melbourne Stroke Incidence Study (NEMESIS), a communi-
ty-based stroke incidence study that provides the most realis-
tic picture of current-practice stroke care, including post acute 
care in Australia.
More efficacy data are available nowadays, such as that from 
the study by Chambers et al.,
15 who used clinical data includ-
ing trials, meta-analysis, and prospective cohort studies such 
as the Oxfordshire Community Stroke Project and the North-
ern Manhattan Stroke Study. Sandercock et al.
16 estimated ef-
ficacy based on a systematic review of all relevant randomized 
trials supplemented by data from a local stroke registry, the Lo-
thian Stroke Register (LSR). The LSR data items analyzed 
included the length of hospital stay, the score on the modified Cost-Effectiveness of Plasminogen Activator
120  J Clin Neurol 2010;6:117-126
T
a
b
l
e
 
1
.
 
S
u
m
m
a
r
y
 
o
f
 
m
e
t
h
o
d
o
l
o
g
i
c
a
l
 
a
p
p
r
o
a
c
h
e
d
 
u
s
e
d
 
i
n
 
c
o
s
t
-
e
f
f
e
c
t
i
v
e
n
e
s
s
 
s
t
u
d
i
e
s
 
o
f
 
r
e
c
o
m
b
i
n
a
n
t
 
t
i
s
s
u
e
 
p
l
a
s
m
i
n
o
g
e
n
 
a
c
t
i
v
a
t
o
r
 
(
r
t
P
A
)
 
f
o
r
 
t
h
e
 
t
r
e
a
t
m
e
n
t
 
o
f
 
a
c
u
t
e
 
i
s
c
h
e
m
i
c
 
s
t
r
o
k
e
S
t
u
d
y
P
e
r
s
p
e
c
t
i
v
e
M
o
d
e
l
i
n
g
 
m
e
t
h
o
d
M
e
a
s
u
r
e
m
e
n
t
M
a
i
n
 
s
o
u
r
c
e
 
o
f
 
c
l
i
n
i
c
a
l
 
d
a
t
a
C
o
s
t
s
(
d
i
s
c
o
u
n
t
 
r
a
t
e
)
B
e
n
e
fi
t
s
(
d
i
s
c
o
u
n
t
 
r
a
t
e
)
F
a
g
a
n
 
e
t
 
a
l
.
 
(
U
S
A
)
1
3
U
S
 
h
e
a
l
t
h
c
a
r
e
 
s
y
s
t
e
m
M
a
r
k
o
v
 
m
o
d
e
l
i
n
g
M
o
n
t
e
 
C
a
r
l
o
 
s
i
m
u
l
a
t
i
o
n
T
i
m
e
 
h
o
r
i
z
o
n
:
 
3
0
 
y
e
a
r
s
D
i
r
e
c
t
 
c
o
s
t
s
 
(
5
%
 
p
e
r
 
y
e
a
r
)
Q
A
L
Y
s
 
(
5
%
 
p
e
r
 
y
e
a
r
)
N
I
N
D
S
 
r
t
P
A
 
t
r
i
a
l
S
i
n
c
l
a
i
r
 
e
t
 
a
l
.
 
(
C
a
n
a
d
a
)
1
4
C
a
n
a
d
i
a
n
 
h
e
a
l
t
h
c
a
r
e
 
 
s
y
s
t
e
m
M
a
r
k
o
v
 
m
o
d
e
l
i
n
g
M
o
n
t
e
 
C
a
r
l
o
 
s
i
m
u
l
a
t
i
o
n
T
i
m
e
 
h
o
r
i
z
o
n
:
 
3
0
 
y
e
a
r
s
D
i
r
e
c
t
 
c
o
s
t
s
 
(
5
%
 
p
e
r
 
y
e
a
r
)
Q
A
L
Y
s
 
(
3
%
 
p
e
r
 
y
e
a
r
)
N
I
N
D
S
 
r
t
P
A
 
t
r
i
a
l
C
h
a
m
b
e
r
s
 
e
t
 
a
l
.
 
(
U
K
)
1
5
U
K
 
h
e
a
l
t
h
c
a
r
e
 
a
n
d
 
 
s
o
c
i
e
t
a
l
 
 
p
e
r
s
p
e
c
t
i
v
e
s
S
t
r
o
k
e
 
O
u
t
c
o
m
e
 
M
o
d
e
l
 
 
w
i
t
h
 
s
e
m
i
-
M
a
r
k
o
v
 
p
r
o
c
e
s
s
T
i
m
e
 
h
o
r
i
z
o
n
:
 
5
 
y
e
a
r
s
D
i
r
e
c
t
 
c
o
s
t
s
 
(
6
%
 
p
e
r
 
y
e
a
r
)
Q
A
L
Y
s
 
(
6
%
 
p
e
r
 
y
e
a
r
)
P
u
b
l
i
s
h
e
d
 
l
i
t
e
r
a
t
u
r
e
 
(
e
.
g
.
,
 
O
x
f
o
r
d
s
h
i
r
e
 
C
o
m
m
u
n
i
t
y
 
S
t
r
o
k
e
 
 
P
r
o
j
e
c
t
)
 
a
n
d
 
e
x
p
e
r
t
 
o
p
i
n
i
o
n
S
t
a
h
l
 
e
t
 
a
l
.
 
(
U
S
)
1
7
U
S
 
s
o
c
i
e
t
a
l
 
p
e
r
s
p
e
c
t
i
v
e
A
 
d
i
s
c
r
e
t
e
-
e
v
e
n
t
 
 
s
i
m
u
l
a
t
i
o
n
 
m
o
d
e
l
T
i
m
e
 
h
o
r
i
z
o
n
:
 
l
i
f
e
t
i
m
e
B
o
t
h
 
d
i
r
e
c
t
 
a
n
d
 
 
i
n
d
i
r
e
c
t
 
c
o
s
t
s
 
(
3
%
 
p
e
r
 
y
e
a
r
)
Q
A
L
Y
s
 
(
3
%
 
p
e
r
 
y
e
a
r
)
N
I
N
D
S
 
r
t
P
A
 
t
r
i
a
l
S
a
n
d
e
r
c
o
c
k
 
e
t
 
a
l
.
 
(
U
K
)
1
6
U
K
 
h
e
a
l
t
h
c
a
r
e
 
a
n
d
 
 
p
e
r
s
o
n
a
l
 
s
o
c
i
a
l
 
s
e
r
v
i
c
e
s
 
M
a
r
k
o
v
 
m
o
d
e
l
i
n
g
M
o
n
t
e
 
C
a
r
l
o
 
s
i
m
u
l
a
t
i
o
n
T
i
m
e
 
h
o
r
i
z
o
n
:
 
1
2
 
m
o
n
t
h
s
 
 
a
n
d
 
l
i
f
e
t
i
m
e
D
i
r
e
c
t
 
c
o
s
t
s
 
(
6
%
 
p
e
r
 
y
e
a
r
)
Q
A
L
Y
s
 
(
6
%
 
p
e
r
 
y
e
a
r
)
C
o
c
h
r
a
n
e
 
s
y
s
t
e
m
a
t
i
c
 
r
e
v
i
e
w
 
 
a
n
d
 
d
a
t
a
 
f
r
o
m
 
t
h
e
 
L
o
t
h
i
a
n
 
 
S
t
r
o
k
e
 
R
e
g
i
s
t
e
r
M
o
o
d
i
e
 
e
t
 
a
l
.
 
(
A
u
s
t
r
a
l
i
a
)
1
8
A
u
s
t
r
a
l
i
a
n
 
h
e
a
l
t
h
 
s
e
c
t
o
r
M
O
R
U
C
O
S
:
 
d
e
t
a
i
l
e
d
 
m
o
d
e
l
 
c
o
m
p
r
i
s
i
n
g
 
f
o
u
r
 
m
o
d
u
l
e
s
:
 
 
n
a
t
u
r
a
l
 
h
i
s
t
o
r
y
,
 
c
o
s
t
s
,
 
 
o
u
t
c
o
m
e
s
,
 
a
n
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
T
i
m
e
 
h
o
r
i
z
o
n
:
 
l
i
f
e
t
i
m
e
D
i
r
e
c
t
 
c
o
s
t
s
 
(
5
%
 
p
e
r
 
y
e
a
r
)
D
A
L
Y
s
 
(
5
%
 
p
e
r
 
y
e
a
r
)
N
E
M
E
S
I
S
M
a
r
 
e
t
 
a
l
.
 
(
S
p
a
i
n
)
1
9
S
p
a
n
i
s
h
 
s
o
c
i
e
t
a
l
 
 
p
e
r
s
p
e
c
t
i
v
e
M
a
r
k
o
v
 
m
o
d
e
l
i
n
g
M
o
n
t
e
 
C
a
r
l
o
 
s
i
m
u
l
a
t
i
o
n
T
i
m
e
 
h
o
r
i
z
o
n
:
 
3
0
 
y
e
a
r
s
B
o
t
h
 
d
i
r
e
c
t
 
a
n
d
 
 
i
n
d
i
r
e
c
t
 
c
o
s
t
s
 
(
3
%
 
p
e
r
 
y
e
a
r
)
Q
A
L
Y
s
 
(
3
%
 
p
e
r
 
y
e
a
r
)
N
I
N
D
S
 
r
t
P
A
 
t
r
i
a
l
E
h
l
e
r
s
 
e
t
 
a
l
.
 
(
D
e
n
m
a
r
k
)
2
0
D
a
n
i
s
h
 
h
e
a
l
t
h
c
a
r
e
-
s
y
s
t
e
m
 
 
p
e
r
s
p
e
c
t
i
v
e
M
a
r
k
o
v
 
m
o
d
e
l
i
n
g
M
o
n
t
e
 
C
a
r
l
o
 
s
i
m
u
l
a
t
i
o
n
T
i
m
e
 
h
o
r
i
z
o
n
s
:
 
1
,
 
2
,
 
3
,
 
a
n
d
 
 
3
0
 
y
e
a
r
s
D
i
r
e
c
t
 
c
o
s
t
s
 
(
5
%
 
p
e
r
 
y
e
a
r
)
Q
A
L
Y
s
 
(
5
%
 
p
e
r
 
y
e
a
r
)
M
e
t
a
-
a
n
a
l
y
s
i
s
 
o
f
 
s
i
x
 
l
a
r
g
e
 
 
r
a
n
d
o
m
i
z
e
d
 
s
t
u
d
i
e
s
M
O
R
U
C
O
S
:
 
M
o
d
e
l
 
o
f
 
R
e
s
o
u
r
c
e
 
U
t
i
l
i
z
a
t
i
o
n
,
 
C
o
s
t
s
,
 
a
n
d
 
O
u
t
c
o
m
e
s
 
f
o
r
 
S
t
r
o
k
e
,
 
Q
A
L
Y
s
:
 
q
u
a
l
i
t
y
-
a
d
j
u
s
t
e
d
 
l
i
f
e
-
y
e
a
r
s
,
 
D
A
L
Y
s
:
 
d
i
s
a
b
i
l
i
t
y
-
a
d
j
u
s
t
e
d
 
l
i
f
e
-
y
e
a
r
s
,
 
N
I
N
D
S
:
 
N
a
t
i
o
n
a
l
 
I
n
s
t
i
t
u
t
e
 
o
f
 
N
e
u
-
r
o
l
o
g
i
c
a
l
 
D
i
s
o
r
d
e
r
s
 
a
n
d
 
S
t
r
o
k
e
,
 
N
E
M
E
S
I
S
:
 
N
o
r
t
h
 
E
a
s
t
 
M
e
l
b
o
u
r
n
e
 
S
t
r
o
k
e
 
I
n
c
i
d
e
n
c
e
 
S
t
u
d
y
. Jung KT et al.
www.thejcn.com  121
Rankin Scale (mRS), the occurrence of recurrent stroke, death 
from recurrent stroke, and death from all causes up to 12- months 
after the index stroke. Ehlers et al.
20 extracted efficacy data 
from a meta-analysis of six large-scale, randomized, and place-
bo-controlled studies of thrombolytic therapy (Table 1).
20
Outcomes considered
As described above, all of the studies reviewed were undertak-
en from different perspectives (i.e., societal, healthcare system, 
or mixed). Many experts consider a societal perspective to 
be highly appropriate for carrying out economic evaluations 
of healthcare interventions. However, only two of the studies 
were performed from the societal perspective and included di-
rect and indirect costs.
17,19 To measure direct costs, the stud-
ies used published literature and hospital records. Indirect 
costs were measured based on the average daily wages report-
ed by the United States Bureau of Labor Statistics, the Sakont-
zen questionnaire, and the matrix of societal needs defined 
by a committee of social service experts from the province of 
Gipuzkoa, Spain.
19 Other studies included only direct costs 
based on published literature, local surveys, expert opinions, 
and hospital records. Since the healthcare system in each coun-
try is different, the components of direct cost evaluated by 
these studies differ markedly. In our review, two studies used 
a microcosting approach and listed key unit costs and quanti-
ties of resources base on hospital records and literature.
18,20 
The precision in costing has also varied. The least-precise 
estimates are likely to be based on average per diems (or daily 
costs), while the most-precise estimates are likely to be based 
on microcosting, in which each component of the resource 
used (e.g., laboratory tests or drugs) is estimated and a unit cost 
is derived for each.
Seven of the studies reviewed herein used QALYs as the he-
alth outcome summary measure to compare health outcomes 
of different types. A QALY is a year lived whilst weighted by 
the quality of life during that time. A patient’s quality of life 
depends on his or her current health state.
13-17,19,20 Fagan et al.,
13 
Sinclair et al.,
14 Chamber et al.,
15 Stahl et al.,
17 Sandercock et 
al.,
16 and Ehlers et al.
20 categorized the health state based on 
the mRS as follows: no symptoms (R0), no significant disabil-
ity (R1), minimal disability (R2), moderate disability (R3), 
moderate to severe disability (R4), severe disability (R5), and 
dead. Mar et al.
19 used the  European Quality of Life Question-
naire (EuroQol) with a random sampling of patients to deter-
mine values for the utilities of a health state. Moodie et al.
18 
used DALYs to estimate the health gain attributable to each 
intervention (Table 1).
Cost-effectiveness results of the studies
All of the studies reviewed herein concluded that thromboly-
sis treatment can be a cost-effective strategy, especially in the 
long term. Fagan et al.
13 estimated an increase in hospitaliza-
tion costs of US$ 1.7-million and decreases in rehabilitation 
and nursing home costs of US$ 1.4-million and US$ 4.8-mil-
lion, respectively, per 1,000 eligible treatment patients, for a 
healthcare system that includes care facilities from acute 
through to long term. Sinclair et al.
14 estimated a lifetime cost 
difference of 3.8-million Canadian dollars (Can$) in favor of tPA 
versus no tPA (Can$-3,800/patient). In the hypothetical co-
hort, tPA treatment resulted in 13,130-QALYs, versus 9,670- 
QALYs with no tPA treatment. This translated into a net ben-
efit of 3,460 additional QALYs per 1,000 patients (i.e., 3.46- 
QALYs/patient). Chamber et al.
15 demonstrated that rtPA in 
acute ischemic stroke administered within 3-hours of symp-
tom onset could result in 155 additional QALYs per 1,000 
patients, at a cost saving of €2.33-million, suggesting that in 
treated patients, the savings related to disability and long-term 
care considerably outweigh any potential extra costs of acute 
therapy, given a broad cost perspective and a time horizon of 
5-years. Stahl et al.
17 found that the NINDS-compliant strate-
gy including t-PA treatment resulted in an average QALYs 
value of 3.64, versus 3.63 QALYs for the base case, at an ap-
proximate cost of US$ 434/patient.
Sandercock et al.
16 showed that over the cohort lifetime, ap-
plying rtPA becomes the dominant strategy. Treatment with 
rtPA was more effective (gain in QALYs of 3.63 per 100 pa-
tients treated), less expensive than standard treatment (cost 
savings of €350,532), and resulted in a reduced cost of €96,565/ 
QALY. Moodie et al.
18 estimated that aspirin intervention was 
effective for reducing stroke mortality, but required a higher 
overall cost because of increased stroke survival (US$ 1.7-mil-
lion), whereas rtPA effectively reduced post-stroke disability 
and led to long-term cost savings (US$ 0.4-million). Mar et 
al.
19 calculated that the ICER obtained with thrombolytic 
treatment had values of €3,841/QALY and €2,733/QALY for 
men and women, respectively, without consideration of soci-
etal cost, but produced a net saving of €14,913/QALY for men 
and €16,021/QALY for women when the societal costs were 
incorporated in the model. Ehlers et al.
20 calculated the ICER 
for 1, 2, 3, and 30-years. In that study, short-term thromboly-
sis (first year) increased the net health costs, but the picture 
changed after 2-years when, given the assumptions about ef-
fect and costs, thrombolysis became cost-effective. In the long 
term (30-years), IV thrombolysis with rtPA was the dominant 
strategy compared with conservative treatment (Table 2).
The overall results are summarized in Table 3. IV rtPA was 
associated with an acceptable increase in short-term cost (rang-
es: US$ 36-236/patient, US$ 29,148-55,591/QALY), and a 
net long-term cost saving that was higher from a societal per-
spective (ranges: -US$ 12,043 to -US$ 630/patient, -US$ Cost-Effectiveness of Plasminogen Activator
122  J Clin Neurol 2010;6:117-126
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207,253 to -US$ 21,938/QALY) than from a healthcare-sys-
tem perspective (ranges: -US$ 5,811 to US$ 5,415/patient, 
-US$ 41,137 to US$ 4,662/QALY).
Discussion
Our study shows that IV rtPA is associated with an acceptable 
increase in short-term cost and a net cost saving in the long 
term; more favorable estimates were obtained when involv-
ing the societal perspective. At the same time, we also found 
considerable variations in the methodological approaches, 
data used, and results obtained in previous studies on the 
cost-effectiveness of IV rtPA. This indicates the need for care-
ful interpretation of the individual studies in light of their 
methodological robustness, and further study to evaluate the 
cost-effectiveness of IV rtPA in the context of Korean data.
Health economic evaluation is considered increasingly im-
portant in health policy decision making, including insurance 
coverage and resource allocation, and in turn has huge influ-
ences on clinical practice. However, since the results of cost-
effectiveness could be susceptible to modeling assumptions, 
critical appraisal and judicious interpretation of cost-effective-
ness research is essential, and these analyses should also be 
systematically updated as new research emerges.
To our knowledge, the present study is the most extensive 
systematic review of the cost-effectiveness of the use of rtPA 
in acute ischemic stroke by modeling approach. Economic 
evaluation using the modeling approach has unique strengths 
and drawbacks when compared to economic evaluation along-
side clinical trials. Although modeling approaches were un-
able to provide high internal validity, which can be optimized 
in randomized clinical trials, they rarely examine the long-term 
consequences of a given intervention. However, they could be 
utilized in situations where the relevant clinical trials and ob-
servational data are constrained by the range of outcome data 
collected or the length of follow-up. Thus in practice, model-
ing approaches may have better external validity, and are there-
fore highly desirable in health economic evaluations.
35
The greatest strength of our study is the comprehensiveness 
of the data reviewed, which were from six countries that used 
various sources of clinical and cost data, and adopted various 
perspectives and modeling assumptions (i.e., short- and long-
term time horizons). Despite these differences in model struc-
ture and input variables, the analyzed studies demonstrated 
that applying rtPA is cost-effective, in all cases producing cost 
savings in the long-term.
We also found large variations in the estimates of ICER am-
ong the studies, some of which can be explained. First, eco-
nomic modeling is highly susceptible to assumptions about 
clinical parameters implicit in a model, including the life ex-
pectancy, mortality hazard ratio, and utility. For example, the 
Fagan et al.
13 study projected that long-term mortality rates 
beyond the first poststroke year are the same across all five 
levels of mRS poststroke disability. However, the subsequent 
UK Lothian cohort study
36 and the Swedish Riks-Stroke co-
hort study
37 have shown that long-term life expectancy de-
creases monotonically as the mRS level increases. In this 
sense, we can assume that the Fagan et al.
13 study probably un-
derestimated the effectiveness of IV rtPA. On the other hand, 
in other large trials conducted in Europe [i.e., the European 
Cooperative Acute Stroke Study (ECASS) and ECASS-II],
38 
IV rtPA was not as effective as was shown in the NINDS 
rtPA trial. So, in this regard, we can assume that earlier cost-
effectiveness studies based on the NINDS trial,
13,14,17 includ-
ing that of Fagan et al.,
13 could have overestimated the cost-
effectiveness of IV rtPA relative to later studies that were based 
on systematic reviews or meta-analyses.
16,20 Second, economic 
modeling is also highly susceptible to the other assumptions 
used in the model, including the model structure, cost of care, 
and discount rate. Fagan et al.
13 and Sinclair et al.
14 used the 
same clinical data, but produced hugely different QALYs 
and cost-saving results. Differences in the modeling methods 
and costs of care between the USA and Canada could explain 
this difference. We therefore consider that more valid and 
consistent methods should be used in future cost-effective-
ness analysis or IV rtPA.
While the cost-effectiveness of rtPA treatment appears very 
convincing across studies, economic evaluations need to be 
checked in each country due to intercountry variations in clini-
cal practice patterns and healthcare resources. Cost-effective-
ness analysis requires information on an intervention’s effec-
tiveness and country-specific sources of epidemiological and 
resource utilization data, most of which are not readily avail-
able in Korea. Future research should include direct econom-
ic evaluation or rtPA use from a Korean perspective.
Apart from the theoretical cost-effectiveness of the drug, 
implementation of the strategy is another factor. The propor-
tion of eligible patients who are receiving this costly but si-
multaneously cost-saving IV rtPA treatment in Korea is not 
well known, but it was reported for other countries that only 
about 20% of stroke patients arrive in time to be treated with 
thrombolysis, and only 1-8% of all stroke patients are actual-
ly treated with IV rtPA.
39 Interorganizational, intraorganiza-
tional, medical, and psychological barriers hamper the broad 
implementation of thrombolysis for acute ischemic stroke.
40 
If the cost-effectiveness of rtPA is accepted, every single mea-
sure should be considered in order to increase the proportion 
of patients who may benefit from the treatment. Since a short 
door-to-door time is critical for the clinical effectiveness of 
rtPA treatment, investment in improving the system for deliv- Jung KT et al.
www.thejcn.com  125
ering emergency healthcare and public education should be 
considered. Since the administration of rtPA requires pretreat-
ment imaging
41 and careful follow-up, the appropriate care 
setting and availability of a trained physician are essential. 
Designation of stroke centers (both primary and comprehen-
sive) to improve the organization and delivery of care to 
stroke patients might be considered from the cost-effective-
ness perspective.
42,43
In summary, based on a comprehensive review of the avail-
able literature, we conclude that IV rtPA is a cost-effective 
strategy for the management of acute ischemic stroke that 
might reduce healthcare costs as well as patient disability. Fur-
ther cost-effectiveness research and development of a public 
health strategy is warranted to optimize the use of rtPA in Korea.
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